- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
ESC/WCC: No Peripheral Arterial Disease Benefit for Coumadin-Aspirin
BARCELONA, Spain -- An antiplatelet-anticoagulant duo, which showed promise in treating coronary disease, increased the risk of life-threatening bleeding events in patients with peripheral arterial disease, according to results of a trial reported here.
BARCELONA, Spain, Sept. 6 -- An antiplatelet-anticoagulant duo, which showed promise in treating coronary disease, increased the risk of life-threatening bleeding events in patients with peripheral arterial disease, according to results of a trial reported here.
Four percent of patients randomized to Coumadin (warfarin) plus aspirin had life-threatening bleeding events versus 1.2% of patients treated with aspirin alone (P
The WAVE study recruited 2,161 patients and evenly randomized them to the Coumadin-plus-aspirin regimen or aspirin alone. The average age of patients was 64, and 74% were women. Twenty-nine percent of the participants were current smokers, and 81% had limb peripheral arterial disease. The average blood pressure in both arms was 137/78 mm Hg. At baseline, 98% of the participants were on antiplatelet therapy.
In each group treatment was titrated to reach International Normalization Ratio (INR) levels of 1.8 to 3.5.
